Reopened USAntibiotics penicillin facility to relieve US dependence on Chinese antibiotics: Jackson Healthcare
The facility will be able to manufacture and stockpile a five-year supply of amoxicillin for the US
USAntibiotics' recently reopened Bristol, Tennessee penicillin manufacturing facility will relieve US dependence on China for antibiotic supply once it comes online, according to the new owners of the site, Jackson Healthcare.
The plant, formerly owned by Neopharma, had slipped into bankruptcy and ceased operations in 2020 before being purchased by Jackson Healthcare earlier this year.
"As the first doses of USAntibiotics' life-saving drugs move down the assembly line, America will have declared its independence from Chinese antibiotics," said Rick Jackson, founder, CEO, and chairman of Jackson Healthcare. "Our mission is to solve our nation's reliance on foreign Amoxicillin and create a secure stockpile that will stand the test of time."
Upon reopening, USAntibiotics will be the only American company able to manufacture the popular antibiotics commonly known as Amoxil (amoxicillin) and Augmentin (amoxicillin clavulanate).
When the 360,000-sq. ft facility comes online, it will have the capacity to produce 300 million capsules and two billion tablets annually, meeting 100% of US amoxicillin demand, according to Jackson Healthcare.
Thirty percent of all antibiotics prescribed in the US each year are amoxicillin.
The facility can also manufacture and stockpile a five-year supply of amoxicillin for the US, a move that represents a complete reversal of the current situation whereby every dose is sourced from outside the US, primarily China, due to years of declining pharmaceutical production capacity in the US.
Earlier this year, US President Joe Biden ordered a review of crucial US supply chains, including pharmaceuticals.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance